

International Journal of Scientific Research and Reviews

Antiproliferative BT008B inhibits neovascularization in inflammatory ascites tumour model

Shamanth Neralagundi H.G¹, Mohammed Al-Ghorbani², Shaukath Ara Khanum², Manjunatha .H³, Prabhakar B.T.^{1*}

¹Molecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College (Autonomous), Kuvempu University, Shivamogga, Karnataka 577203, India.

²Dept. of Chemistry, Yuvaraja's College, University of Mysore, Mysore 570005, Karnataka, India

³Dept. of PG studies and Research in Biotechnology, Jnana Sahyadri Shankargahatta, Shivamogga, Karnataka 577203, India.

ABSTRACT

Inflammation is one of the hall mark of cancer, inflammatory angiogenesis plays vital role in inducing cancer, were tumour microenvironment orchestring different inflammatory cytokines. Benzophenone compounds have proven their ability as potent anticancer moiety among them BT008B, a benzophenone tagged pyridine molecule was screened against different cancer cell lines and showed its effect as potent cytotoxic molecule against EAC and DLA with 3.8 μ M and 8.5 μ M respectively. Further, BT008B showed its antiproliferative effect in *in-vivo* ascites tumour model system with the decrease in the ascites volume, cell count, tumour growth in BT008B treated mice compared to the untreated and the survivability of the treated mice was increased. Peritoneal angiogenesis of the BT008B was reduced compared to the untreated mice.

KEY WORDS: Inflammation, angiogenesis, Benzophenone

***Corresponding author:**

Dr. Prabhakar.B.T

Assistant professor, Molecular Biomedicine Laboratory

Postgraduate Department of Studies and Research in Biotechnology

Sahyadri Science College, Kuvempu University, Karnataka 577203, India.

E mail - Prabhakarbt1@kussc.org , Mob. No. - +91 9632872467

INTRODUCTION

Inflammation is a multifaceted biological reaction of vascular tissues to harmful spurs, such as pathogens, damaged cells or irritants¹. In recent years, inflammation has taken its stage to be listed as the seventh hallmark of cancer². About 25% of all cancers are linked to chronic inflammation and inflammation induced through external sources like exposure to environmental or to the infectious pathogens these studies were confirmed through epidemiological and clinical studies³. Inflammation and cancer are linked to each other, chronic inflammation may lead to cancer where inflammatory cells infiltrate tumours leading to cancer^{4, 5}. Tumour microenvironment reminds you of an inflammatory site where recruitment of numerous pro-inflammatory cytokines is seen. Although it is now clear that proliferation of cells alone does not cause cancer, sustained cell proliferation in an environment rich in inflammatory cells, growth factors, activated stroma, and DNA-damage-promoting agents, certainly potentiates and/or promotes neoplastic risk⁶. Angiogenesis is the process which involves growth and remodelling of new vascular system from the initial blood vessels leading to formation of neo branching of complex network system of blood vessels⁷. Chronic inflammation and angiogenesis are the two processes that are coordinated with each other in the development of cancer. Inhibiting inflammatory angiogenesis is one of the key strategies in blocking the cancer. In the quest of searching anticancer drugs Benzophenones was our answer. Benzophenones, The pharmacologically active molecules which are available by both natural and synthetic means⁸ these derivatives are used in medicine research for their familiar effectiveness against various pathological conditions including cancer^{9,10}. Benzophenone conjugated analogues are known as potent inhibitors targeting angiogenesis^{11,12}. Benzophenone tagged pyridine While, pyridine or nicotinic acid is well known for its biological activity against carcinogenesis^{13,14} our group has identified one of the compounds Benzophenone tagged pyridine BT008B (6-Hydroxy-nicotinic acid N0-{2-[2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]-acetyl}-hydrazide) which is known for its potentiality to induce apoptosis by degrading ICAD from CAD and inducing nuclear translocation of CAD¹⁵ by taking the following consideration compound BT008B was chosen to screen against multiple cancer cell lines both *in vitro* and *in vivo* system.

MATERIALS AND METHOD

Cell culture and In-vitro treatment

Human cancer cell lines lung adenocarcinoma (A549), breast adenocarcinoma (MCF-7), melanoma (A375), Hepatocellular carcinoma (HUH-7, HepG2) and murine origin Dalton's Ascites Lymphoma (DLA), Ehrlich-Lette Ascites-E (EAC), melanoma (B16F10), cells were cultured in

DMEM and RPMI media (Gibco-Invitrogen, USA), respectively with 10% FBS(In vitrogen, USA), with necessary antibiotic and antimetabolic (Sigma Aldrich, USA) supplied with 5% CO₂ at 37 °C. The cytotoxic effect of BT008B (0, 10, 20, 50, and 100 µM for 48 hrs) was evaluated by cytotoxic assays trypan blue dye exclusion assay as reported earlier with a suitable vehicle and positive control.

Trypan blue dye exclusion assay

Cytotoxic effect of BT008B was checked through trypan blue dye exclusion assay against A549, MCF-7, and Huh-7, Hepg2, B16F10, A375, DLA and EAC cell lines. Cells were cultured and treated with or without compound BT008B and incubated for 48hr with the supply of 5% CO₂ and after 48hrs cells were collected and determination of IC₅₀ value of BT008B was done by resuspending the cells in 0.4% trypan blue^{16, 17}.

Animal models and ethics

Healthy Swiss albino mice aged 5–6 weeks, weighing 25–30 g were used throughout the study. The mice were grouped in polyacrylic cages with not more than ten animals per cage with adequate food and water supply. The present study involving all the animal experimentations was approved by the Institutional Animal Ethics Committee (IAEC), National College of Pharmacy, Shivamogga, India, in accordance with the CPCSEA guidelines for laboratory animal facility (NCP/IAEC/CL/101/05/2012-13).

Determining the LD50 value of compound BT008B

Normal Swiss albino mice divided into 5 groups (n = 6) were subjected to the acute toxicity studies. The LD₅₀ of compound BT008B was determined by intraperitoneal administration of BT008B as per the standard CPCSEA guidelines. To check the adverse effect of the compound BT008B (75 mg/kg body weight) in Swiss albino mice haematological and serum profiles were done as per the methods described previously¹⁸

Tumour models and treatment

In-vivo EAC Ascites tumour model system was developed in Swiss albino mice, EAC cells (1×10⁶ cells) were injected into the peritoneal region of normal Swiss albino mice and weight of transplanted mice was monitored daily. On the onset of tumour growth i.e. on the fourth day after transplantation compound BT008B was treated with the concentration of 50 and 75mg/kg body weight of the mice and appropriate Vehicle control was kept. On the 10th day mice were sacrificed

and tumour parameters like ascites volume, packed cell volume, tumour growth and survivality of the control and treated mice was noted ¹⁹.

Peritoneal angiogenesis

Ascites tumour was induced by injecting EAC tumour cells into peritoneal region of Swiss albino mice after the onset of tumour i.e. on the 4th day compound BT008B was treated (50, 75 mg/Kg body weight) for three doses to the intraperitoneal region on every alternative days on the 10th day mice was sacrificed .The peritoneal region of BT008B treated and untreated mice was observed and the micro vessel density in the peritoneal region was observed.

RESULTS

BT008B screened against multiple cell line to check its cytotoxic effect

BT008B(Figure1) was screened against human origin A549, MCF-7, Huh-7, Hepg2, B16F10, A375 and murine origin DLA and EAC cell lines.BT008B showed more cytotoxic effect in EAC with IC₅₀ value of 3.8 μM and in DLA IC₅₀ value was found to be 8.5 μM, effect of BT008B on A549, MCF-7, Huh-7, HepG2, B16F10, A375 was not found promising (Figure2).




Figure 1. Structure of compound BT008B (6-Hydroxy-nicotinic acid N0-(2-[2-chloro-6-fluoro-4-(4-fluorobenzoyl)-phenoxy]-acetyl)-hydrazide).

BT008B induces antineoplastic effect in Ascites tumour model system

To evaluate the *In vivo* antineoplastic effect of BT008B, EAC ascites model system was developed by injecting 1×10⁶ EAC cells into the peritoneum region of Swiss albino mice after the onset tumour BT008B was treated in dose dependent manner i.e. 50mg and 75 mg/Kg body weight, for three doses in alternative days.




Figure2. Graphs showing IC₅₀ value of BT008B In-vitro cytotoxic effect of Compound BT008B against multiple cancer cell lines.

It was found that there was decrease in the tumour in dose dependent manner, ascites volume, cell count and tumour volume was found to be low in BT008B treated mice compared to the untreated mice(Figure3). There was decrease in the micro vessel density of the BT008B treated mice compared to untreated and there was increase in the survivability of the BT008B treated mice compared to the untreated mice (Figure 4).




Figure 3. *In vivo* screening of BT008B against EAC cells compound BT008B was given in two different concentration 50mg and 75mg a) Physical morphology of tumour bearing mice and treated mice with two different concentration, b) Dose dependent decrease in ascites volume compared to the control, c) Decreased cell count in BT008B treated mice In dose dependent manner compared to the untreated mice, d) Decrease in the tumor growth in BT008B treated mice, e) Prolonged survivability of BT008B treated mice can be seen compared to the control mice



Figure 4. Reduced peritoneal angiogenesis in dose dependent manner in BT008B treated mice

DISCUSSION

Inflammation is one of the emerging hallmark for cancer², inflammatory environment mimics the tumour microenvironment³. Angiogenesis is development of new blood vessels in controlled manner²⁰ angiogenesis plays major role in tumourgenesis during tumour condition there is increase in the angiogenesis, which help tumour cells in providing essential nutrients and growth factors. Targeting inflammatory angiogenesis plays vital step in reducing tumour^{4, 5}. Benzophenones are known for their potent anticancer activity^{9, 10}. Previously our group as reported different benzophenone tagged molecules acting as potent anticancer drugs against various cancer cell lines^{11, 12&18} as in the process of developing the drug benzophenone was tagged with pyridine molecule, pyridine molecule is known for its cytotoxic effect^{13,14} benzophenone tagged pyridine molecule BT008B (6-Hydroxy-nicotinic acid N0-{2-[2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]-acetyl}-hydrazide) is one such kind of molecule which showed its potency against tumour cells, the flour group present in the molecule (Fig.1) plays vital role in making compound more cytotoxic molecule this was checked through structural activity relationship¹⁵ further BT008B was screened against EAC,DLA,A375,A459,B16F10,HuH-7 and HepG2 cell lines through cytotoxic assay trypan blue dye exclusion, cells were treated with or without BT008B in concentration dependent manner(0-100 μ m) and incubated for 48 hrs with the supply of 5% CO₂ in humidified condition, BT008B found to be more cytotoxic in EAC and DLA cell lines with the IC₅₀ value of 3.9 μ m and 8.5 μ m and its effect on other cell lines was not much promising (Fig.2). Further the antiproliferative effect of BT008B was checked through *In-vivo* EAC ascites tumour model system which is one of the foremost inflammatory angiogenesis model system were tumour cells are cultured in peritoneum region of mice, BT008B was treated with two different dose 50mg and 75mg after the onset of tumour in mice and body weight of treated mice and untreated mice was observed daily on the 10th day mice was scarified and different tumour parameters like cell count, ascites volume, tumour growth, survivality was checked there was drastic decrease in the ascites volume of treated mice compared to the untreated, cell count was low in BT008B treated compared to control mice and

tumour growth was reduced in compound treated mice compared to the control mice and survivality of the BT008B was increased two folds more compared to the untreated mice. Peritoneal angiogenesis induced by ascites tumour was measured, increased micro vessel in the peritoneum region of mice indicates the angiogenesis, and peritoneal angiogenesis was reduced in BT008B treated mice compared to the control this was inferred through reduced count of microvessel density in BT008B treated mice compared to the control. By considering the above results BT008B acts as potent angiopreventive drug.

CONFLICT OF INTEREST: The authors declare that there are no conflicts of interest.

ACKNOWLEDGMENTS: Shamanth Neralagundi H.G. acknowledges thankfully for Lady Tata Memorial Trust (LTMT) Mumbai for the JRF award for the year 2015-16.

REFERENCE:

1. Dawit Kidane, Wook Jin Chae, Jennifer Czocho, Kristin A. Eckert, Peter M. Glazer¹, Alfred L. M. Bothwell, and Joann B. Sweasy. Interplay between DNA repair and inflammation, and the link to cancer. *Crit Rev BiochemMol Biol.* 2014; 49(2): 116–139.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100:57–70.
3. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature.* 2004; 431:405–6.
4. Virchow, R. An address on the value of pathological experiments. *Br. Med. J.* 1881; 2: 198–203.
5. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” *The Lancet.* 2001; 357:539–545.
6. Lisa M. Coussens, and Zena Werb. Inflammation and cancer, *Nature.* 2002; 420(6917): 860–867.
7. Carmeliet P. Angiogenesis in life, disease and medicine. *Nature* 2005; 438:932–936.
8. G.E. Henry Jacobs, C.M.S. Carrington, S. McLean, W. Freeholds, Prenylated benzophenone derivatives from Caribbean clusia species (guttiferae). *PlukenetionesBeG and xerophenone A, Tetrahedron* 1999; 1581-1596.

9. E. Kumazawa, K. Hirotsu, S.C. Burford, K. Kawagoe, T. Miwa, I. Mitsui, A. Ejima, Synthesis and Antitumor Activity of Novel Benzophenone Derivatives. *Chem. Pharm. Bull* 1997; 45: 1470-1474.
10. S. Cortez-Maya, E. Cortes Cortes, S. Hernández-Ortega, T. Ramirez Apan, M. Martínez-García. Synthesis of 2-Aminobenzophenone Derivatives and Their Anticancer Activity. *Synth. Commun.* 2012; 42: 46–54.
11. V.L. Ranganath, B.R.V. Avin, P. Thirusangu, T. Prashanth, B.T. Prabhakar, S.A. Khanum. Synthesis, angiopreventive activity, and in vivo tumor inhibition of novel benzophenone–benzimidazole analogues. *Life Sci.* 2013; 93: 904–911.
12. T. Prashanth, P. Thirusangu, B.R. Vijay Avin, V. Lakshmi Ranganatha, B.T. Prabhakar, S.A. Khanum. Synthesis and evaluation of novel benzophenone-thiazole derivatives as potent VEGF-A inhibitors. *Eur. J. Med. Chem.* 2014; 87: 274–283.
13. Y.B. Zhang, W. Liu, Y.S. Yang, X.L. Wang, H.L. Zhu, L.F. Bai, X.Y. Qiu. Synthesis, molecular modeling and biological evaluation of 1, 2, 4-triazole derivatives containing pyridine as potential anti-tumor agents. *Med. Chem. Res.* 2013; 22: 3193–3203.
14. J. Albert, J. Granell, R. Qadir, J. Quirante, C. Calvis, R. Messeguer, J. Badía, L. Baldomà, M. Font-Bardia, T. Calvet. Cyclopalladated benzophenone imines: Synthesis, antitumor activity, cell accumulation, dna interaction, and cathepsin b inhibition. *Organometallics* 2014; 33(24): 7284–7292.
15. Mohammed Al-Ghorbani, Prabhu Thirusangu, H.D. Gurupadaswamy, V. Girish, H.G. ShanthNeralagundi, B.T. Prabhakar, Shaukath Ara Khanum. Synthesis and antiproliferative activity of benzophenone tagged pyridine analogues towards activation of caspase activated DNase mediated nuclear fragmentation in Dalton's lymphoma. *Bioorganic Chemistry* 2016; 65: 73–81.

16. C.J. Lion, C.S. Matthews, G. Wells, T.D. Bradshaw, M.F.G. Stevens, A.D. Westwell. Anti-tumour Properties of Fluorinated Benzothiazole-Substituted Hydroxycyclohexa-2, 5-Dienones ('Quinols'). *Bioorg. Med. Chem. Lett.* 2006; 16: 5005-5008.
 17. Huang ST, Hsei IJ, Chen C. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles. *Bioorg Med Chem.* 2006; 14(17):6106–6119.
 18. B.T. Prabhakar, S.A. Khanum, K. Jayashree, B.P. Salimath, S. Shashikanth, Antitumor and proapoptotic effect of novel synthetic benzophenoneanalogs in ehrlich ascites tumor cells, *Bioorg. Med. Chem. Lett.* 2006; 14: 435- 446.
 19. B.R. Vijay Avin, T. Prabhu, C.K. Ramesh, V. Vigneshwaran, M. Riaz, K. Jayashree, B.T. Prabhakar. New role of lupeol in reticence of angiogenesis, the cellular parameter of neoplastic progression in tumorigenesis models through altered gene expression, *Biochem. Biophys. Res. Commun.* 2014; 448:139–144.
 20. J. Folkman. Opinion: Angiogenesis: an organizing principle for drug discovery? *Nat. Rev. Drug Discov.* 2007;6: 273–286.
 21. Vijay Avin BR, Thirusangu P, Ranganatha VL, FirdouseA, Prabhakar BT, Khanum SA Synthesis and tumor inhibitory activity of novel coumarin analogs targeting angiogenesis and apoptosis. *Eur J Med Chem* 2014; 75:211–221.
-